Obermatt
See Similar Stocks →

Mesoblast

ASX:MSB · AU000000MSB8
BiotechnologySmall

360

42
EV / EBIT1
Price / Owner Earnings91
Owner Earnings Yield1
Dividend Yield1
Price/Sales8
Price/Book42
Return on Capital74
Cash Return on Capital77
Return on Equity80
EBIT Margin18
Gross Profitability42
Accruals46
Owner Earnings Margin37
Sales growth100
Profit growth20
Reinvestment59
Price momentum66
Debt load60
Refinancing43
Debt Payback1
Liquidity25
Analyst ratings86
Opinion Changes50
Price Target Upside60
Market mood53
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Mesoblast doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryAustralia
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeASX
Founded2004
Employees99
Websitemesoblast.com
ISINAU000000MSB8
Last UpdateApr 2, 2026
Indices
ASX 200 (Australia)ASX 300 (Australia)
Themes
Chronic DiseasesRheumatologyStem Cell TherapyCardiovascularImmunologyNephrologyPain ManagementGastroenterologyInflammationBiotechnologyHealth CareScience and Engineering

Description

Mesoblast Limited (Mesoblast) is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the…

Analysis

Middle-of-the-road

Mesoblast Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
64
2026

All-time high

64

Jun 2026

All-time low

35

Mar 2026

Average rank

50

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
—
—
—
Price/Earnings
96
—
—
—
Price/Book
42
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
34
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mesoblast with its peers
Zai Lab
HKG:9688
32
CountryChina
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Clinuvel Pharmaceuticals
ASX:CUV
93
CountryAustralia
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Jyong Biotech
NMQ:MENS
—
CountryTaiwan
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Innovent Biologics
HKG:1801
68
CountryChina
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
GC Biopharma
KSC:006280
52
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Wave Life Sciences
NMQ:WVE
20
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →